Biologics and airway remodeling in severe asthma
Asthma is a chronic inflammatory airway disease resulting in airflow obstruction, which in
part can become irreversible to conventional therapies, defining the concept of airway …
part can become irreversible to conventional therapies, defining the concept of airway …
Molecular targets for biological therapies of severe asthma
Asthma is a heterogeneous respiratory disease characterized by usually reversible
bronchial obstruction, which is clinically expressed by different phenotypes driven by …
bronchial obstruction, which is clinically expressed by different phenotypes driven by …
Biologics in asthma: a molecular perspective to precision medicine
Recent developments in therapeutic strategies have provided alternatives to corticosteroids
as the cornerstone treatment for managing airway inflammation in asthma. The past two …
as the cornerstone treatment for managing airway inflammation in asthma. The past two …
Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives
G Kardas, M Panek, P Kuna, P Damiański… - Frontiers in …, 2022 - frontiersin.org
Patients with moderate-to-severe asthma may now be treated using a variety of monoclonal
antibodies that target key inflammatory cytokines involved in disease pathogenesis. Existing …
antibodies that target key inflammatory cytokines involved in disease pathogenesis. Existing …
Delays related to prior authorization in inflammatory bowel disease
BD Constant, EF de Zoeten, MG Stahl… - …, 2022 - publications.aap.org
BACKGROUND Delays in advancing to biologic therapies are associated with adverse
outcomes in inflammatory bowel disease (IBD). Insurer-mandated prior authorizations have …
outcomes in inflammatory bowel disease (IBD). Insurer-mandated prior authorizations have …
Fc-engineered therapeutic antibodies: recent advances and future directions
DT Abdeldaim, K Schindowski - Pharmaceutics, 2023 - mdpi.com
Monoclonal therapeutic antibodies have revolutionized the treatment of cancer and other
diseases. Fc engineering aims to enhance the effector functions or half-life of therapeutic …
diseases. Fc engineering aims to enhance the effector functions or half-life of therapeutic …
Tezepelumab: a potential new biological therapy for severe refractory asthma
Thymic stromal lymphopoietin (TSLP) is an innate cytokine, belonging to the group of
alarmins, which plays a key pathogenic role in asthma by acting as an upstream activator of …
alarmins, which plays a key pathogenic role in asthma by acting as an upstream activator of …
Biological therapies of severe asthma and their possible effects on airway remodeling
G Kardas, P Kuna, M Panek - Frontiers in immunology, 2020 - frontiersin.org
Asthma is a chronic and heterogenic respiratory tract disorder with a high global prevalence.
The underlying chronic inflammatory process and airway remodeling (AR) contribute to the …
The underlying chronic inflammatory process and airway remodeling (AR) contribute to the …
Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma: real-life evaluation correlated with allergic and non-allergic phenotype …
C Pelaia, C Crimi, A Benfante, MF Caiaffa… - Journal of Asthma …, 2021 - Taylor & Francis
Background Benralizumab can be utilized as add-on biological treatment of severe
eosinophilic asthma. However, so far only a few real-life studies have been published with …
eosinophilic asthma. However, so far only a few real-life studies have been published with …
Real‐life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype
Abstract Background Anti‐interleukin‐5 (IL‐5) monoclonal antibodies can be used as add‐
on biological therapies in allergic and non‐allergic patients with severe eosinophilic asthma …
on biological therapies in allergic and non‐allergic patients with severe eosinophilic asthma …